DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors

Pillay, N., Tighe, A., Nelson, L., Littler, S., Coulson-Gilmer, C., Bah, N., Golder, A., Bakker, B., Spierings, D. C. J., James, D. I., Smith, K. M., Jordan, A. M., Morgan, R. D., Ogilvie, D. J., Foijer, F., Jackson, D. A. & Taylor, S. S., 18-Mar-2019, In : Cancer cell. 35, 3, p. 519-533.e8 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

  • Nisha Pillay
  • Anthony Tighe
  • Louisa Nelson
  • Samantha Littler
  • Camilla Coulson-Gilmer
  • Nourdine Bah
  • Anya Golder
  • Bjorn Bakker
  • Diana C J Spierings
  • Dominic I James
  • Kate M Smith
  • Allan M Jordan
  • Robert D Morgan
  • Donald J Ogilvie
  • Floris Foijer
  • Dean A Jackson
  • Stephen S Taylor

Inhibitors of poly(ADP-ribose) polymerase (PARP) have demonstrated efficacy in women with BRCA-mutant ovarian cancer. However, only 15%-20% of ovarian cancers harbor BRCA mutations, therefore additional therapies are required. Here, we show that a subset of ovarian cancer cell lines and ex vivo models derived from patient biopsies are sensitive to a poly(ADP-ribose) glycohydrolase (PARG) inhibitor. Sensitivity is due to underlying DNA replication vulnerabilities that cause persistent fork stalling and replication catastrophe. PARG inhibition is synthetic lethal with inhibition of DNA replication factors, allowing additional models to be sensitized by CHK1 inhibitors. Because PARG and PARP inhibitor sensitivity are mutually exclusive, our observations demonstrate that PARG inhibitors have therapeutic potential to complement PARP inhibitor strategies in the treatment of ovarian cancer.

Original languageEnglish
Pages (from-to)519-533.e8
Number of pages11
JournalCancer cell
Issue number3
Publication statusPublished - 18-Mar-2019

Download statistics

No data available

ID: 78249798